Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Histopathology|October 15, 2013
Loss of membranous expression of the intracellular domain of EpCAM is a frequent event and predicts poor survival in patients with pancreatic cancerDominic Fong, Patrizia Moser, Armin Kasal, et al.
International Journal of Cancer|March 22, 2016
Predominant expression of truncated EpCAM is associated with a more aggressive phenotype and predicts poor overall survival in colorectal cancerAndreas Seeber, Gerold Untergasser, Gilbert Spizzo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survivalMeri Varga, Peter Obrist, Stephan Schneeberger, et al.
Cancer Letters|April 21, 2006
Methylation status of the Ep-CAM promoter region in human breast cancer cell lines and breast cancer tissueGilbert Spizzo, Guenther Gastl, Peter Obrist, et al.
Bioengineering (Basel, Switzerland)|May 25, 2024
Application of Artificial Intelligence Methods on Osteoporosis Classification with Radiographs-A Systematic ReviewRen Wei Liu, Wilson Ong, Andrew Makmur, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2022
Third dose of SARS-CoV-2 vaccination in hemato-oncological patients and health care workers: immune responses and adverse events - a retrospective cohort studyMaximilian J Mair, Julia M Berger, Manfred Mitterer, et al.
JAMA Oncology|September 30, 2021
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 VaccinationsMaximilian J Mair, Julia M Berger, Anna S Berghoff, et al.
Cancers|September 14, 2024
Oncologic Applications of Artificial Intelligence and Deep Learning Methods in CT Spine Imaging-A Systematic ReviewWilson Ong, Aric Lee, Wei Chuan Tan, et al.
Haematologica|April 19, 2012
High-dose imatinib induction followed by standard-dose maintenance in pre-treated chronic phase chronic myeloid leukemia patients--final analysis of a randomized, multicenter, phase III trialAndreas L Petzer, Dominic Fong, Thomas Lion, et al.
Haematologica|February 11, 2010
High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" studyAndreas L Petzer, Dominik Wolf, Dominic Fong, et al.
Pageof 3